ATRA
Atara Biotherapeutics Inc
8.50$
-0.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +50.0% | +700.0% | +697.9% | +149.6% | +290.4% | +89.4% | +17.9% | +12.2% | -39.5% | -14.6% | +4.6% | -53.0% | |
| – | +95.5% | +489.7% | +1.5% | +63.7% | +37.6% | +46.4% | +52.9% | -0.7% | +4.9% | -0.1% | -15.7% | -40.5% | -63.9% | |
| – | – | +7,231.8% | -4.7% | +62.2% | +37.6% | +47.3% | +54.9% | -2.4% | +11.9% | -93.7% | – | – | – | |
| – | – | -100.3% | – | -111.7% | – | +108.3% | -127.6% | – | -17.4% | -216.9% | – | -301.8% | – | |
| – | -88.9% | +1,433.3% | +530.4% | +941.4% | +569.9% | +77.6% | -84.0% | -21.3% | +134.4% | -60.4% | -70.8% | -79.9% | -100.0% | |
| – | -88.9% | +2,778,666.7% | +164.1% | – | +17.9% | -298.9% | – | -299.7% | – | +811.8% | -39.0% | -93.0% | +110.4% | |
| – | – | – | – | – | – | – | – | -77.3% | -18.2% | -49.9% | – | – | – | |
| – | – | – | -106.6% | -98.0% | +279.8% | +2,001.7% | -10.8% | -77.3% | -18.2% | -49.9% | -84.9% | – | – | |
| – | – | – | -256.7% | +0.0% | – | -105.3% | -8.0% | -20.0% | -34.7% | – | -103.1% | -5.8% | -72.0% | |
| – | +253.0% | +31.7% | +268.9% | -99.8% | +3,862.1% | +1,683.4% | -47.2% | +126.5% | -75.7% | -48.9% | -96.2% | +2,849.4% | -72.8% | |
| – | +275.6% | -162.7% | – | +1,210.0% | +29.0% | -159.3% | – | +825.8% | -174.8% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.